A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes (SURPASS-2)
The reason for this study is to compare the effect of the study drug tirzepatide tosemaglutide on blood sugar levels in participants with type 2 diabetes.
Trial Summary
Key Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Participant must have type 2 diabetes mellitus (T2DM)
Participant must have HbA1c between >7.0% and <10.5%
Participant must be on stable treatment dose of metformin
Participant must be of stable weight
Participants Must Not:
Participant must not have type 1 diabetes
Participant must not have pancreatitis
Participant must not have disorders with slowed emptying of the stomach contents, or have had any stomach surgeries for the purpose of weight loss
Participant must not have a personal or family history of medullary thyroid carcinoma or personal history of multiple endocrine neoplasia syndrome type 2
Participant must not have had a heart attack stroke, or hospitalization for congestive heart failure in the past 2 months
Participant must not have been taking weight loss drugs including over-the-counter medications during the last 3 months
Lilly Trial Alerts
You will complete the questionnaire on another website.YesNo